|
Agreement Covers Phase II Studies for Six Potential Products in 11
Cancer Indications
RESEARCH TRIANGLE PARK, N.C.(BUSINESS WIRE)
Quintiles today announced a strategic alliance with leading global
pharmaceutical company Eisai Co., Ltd. (Tokyo, Japan) to develop six
potential oncology products in Eisai's R&D pipeline. Under the terms of
the agreement, Quintiles oncology experts will conduct Phase II
proof-of-concept studies for 11 solid tumor indications. A key goal of
the alliance is to determine the efficacy of the products in the
shortest possible time in order to bring therapies to market faster for
the benefit of cancer patients worldwide.
The strategic alliance will be structured on a risk-sharing basis, with
Quintiles funding, in part, the design and conduct of the clinical
studies in exchange for success milestone payments. Other financial
terms were not disclosed. The agreement is designed to enable Eisai to
extend its oncology program, increasing the number of indications
investigated for the six potential products, including eribulin (E7389),
E7080, Ontak (denileukin diftitox), E7820, E6201 and E7050.
These assets will remain the property of Eisai, with Quintiles having
development accountability through the Phase II proof-of-concept stage.
In addition to projects covered under the agreement with Quintiles,
Eisai will continue ongoing development of 18 additional indications for
the same six compounds.
Quintiles and Eisai are using the power of partnerships to manage risk
and enable transformation in a rapidly evolving industry where the rules
are changing on all fronts,? said Ron Wooten, Executive Vice President,
Quintiles Corporate Development. Quintiles has first-hand experience in
working with partners to rebalance operational, portfolio and resource
risk. This goes beyond the traditional boundaries of the pharma business
model, offering a more nimble, modular and variable way of leveraging
resources to increase the value of assets.?
This is a significant business model and new strategy for development,?
said Mr. Hideki Hayashi, Senior Vice President and Chief Product
Creation Officer for Eisai. We are maximizing the potential of Eisai's
oncology compounds. I am pleased that Quintiles and Eisai share the same
goals and our incentives are aligned for speed, quality and efficiency.
We will explore multiple indications in parallel so that we can deliver
our compounds as fast, widely and appropriately as possible for cancer
patients benefit.?
Derek Winstanly, Executive Vice President of Strategic Business
Partnerships for Quintiles, said: We are delighted to ally with Eisai
to transform and advance its drug development efforts. This is another
example of how Quintiles can help biopharma companies around the world
increase productivity and improve efficiency, helping to accelerate
availability of drugs to patients.?
Quintiles brings a unique core strength in oncology product development
to the partnership with Eisai. Since 2000, Quintiles has conducted 640
oncology studies, involving more than 131,000 patients at nearly 20,000
investigator sites in 68 countries. The company also helped develop or
commercialize many of today's most widely-prescribed anticancer drugs.
To further support its deep clinical development experience in the 11
solid tumor indications covered by this agreement, Quintiles recently
added further expertise in clinical oncology biomarker development
through its acquisition of Targeted Molecular Diagnostics.
About Quintiles
Quintiles is the only fully integrated biopharmaceutical services
company offering clinical, commercial, consulting and capital solutions
worldwide.The Quintiles network of 23,000 engaged professionals in more
than 50 countries around the globe works with an unwavering commitment
to patients, safety and ethics. Quintiles helps biopharmaceutical
companies navigate risk and seize opportunities in an environment where
change is constant. For more information, please visit www.quintiles.com.
Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc)
company that discovers, develops and markets products throughout the
world. Through a global network of research facilities, manufacturing
sites and marketing subsidiaries, Eisai actively participates in all
aspects of the worldwide health care system. Eisai employs approximately
11,000 employees worldwide. Eisai concentrates its R&D activities in
three key areas:
-
Integrative Neuroscience, including Alzheimer's disease, neuropathic
pain and epilepsy.
-
Integrative Oncology, including anticancer therapies, tumor
regression, tumor suppression and antibodies; supportive cancer
therapies include nausea and vomiting.
-
Vascular/Immunological Reaction including acute coronary syndrome,
atherothrombotic disease and sepsis.
Forward-Looking Statements
This press release contains forward-looking statements,? based on
current expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results
could vary materially from expectations and projections. Risks and
uncertainties include, among other things, general industry conditions;
technological advances and patents attained by competitors; challenges
inherent in the research and development and regulatory processes;
challenges related to product marketing, such as the unpredictability of
market acceptance for new products; inconsistency of treatment results
among patients; the potential for product failures; potential
difficulties in manufacturing; governmental laws and regulations
affecting domestic and foreign operations and the ongoing success of the
collaboration. The parties expressly disclaim any intent or obligation
to update these forward-looking statements except as required to do so
by law.
Quintiles
Susan Landis, Media Relations
919-998-7871
susan.landis@quintiles.com
or
Greg
Connors, Investor Relations
919-998-2000
invest@quintiles.com
Source: Quintiles
|
